Aldosterone and progression of renal disease

Current Opinion in Nephrology and Hypertension

Volumn 17, Issue 1, 2008, Pages 44-50

  Wenzel, Ulrich ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Chronic kidney disease; Proteinuria; Spironolactone; Therapy resistant hypertension

Indexed keywords

ALDOSTERONE; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; RENIN; SPIRONOLACTONE;

BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; DISEASE COURSE; ENZYME REPRESSION; GLOMERULUS FILTRATION RATE; HORMONE INHIBITION; HORMONE RELEASE; HUMAN; HYPERTENSION; INTERSTITIAL NEPHRITIS; PATHOGENESIS; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ALDOSTERONE; ANIMALS; DISEASE PROGRESSION; HUMANS; HYPERTENSION; KIDNEY DISEASES; PROTEINURIA; RECEPTORS, CELL SURFACE;

EID: 37349065141     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e3282f29028     Document Type: Review

References (26)

1. Struthers AD. Aldosterone blockade in cardiovascular disease. Heart 2004; 90:1229-1234.
2. Pondo MP, Hostetter TH. Aldosterone antagonism in chronic kidney disease. Clin J Am Soc Nephrol 2006; 1:668-677.
3. Calhoun DA. Use of aldosterone antagonists in resistant hypertension. Prog Cardiovasc Dis 2006; 48:387-396.
4. Wenzel U. Aldosterone in renal disease, more than retaining sodium and excreting potassium? Kidney Int 2007; 71:374-376.
5. Saha C, Eckert GJ, Ambrosius WT, et al. Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension 2005; 46:481-487.
6. Conn JW, Knopf RF, Nesbit RM. Clinical characteristics of primary aldosteronism from an analysis of 145 cases. Am J Surg 1964; 107:159-172.
7. Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 1996; 98:1063-1068.
8. Arima S, Kohagura K, Xu HL, et al. Nongenomic vascular action of aldosterone in the glomerular microcirculation. J Am Soc Nephrol 2003; 14:2255-2263.
9. Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med 2001; 345:925-926.
10. Chrysostomou A, Pedagogos E, MacGregor L, Becker GJ. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol 2006; 1:256-262. In this study the combination of ACE inhibitor and spironolactone lowered proteinuria significantly better than ACE inhibitor in combination with an AT1 antagonist. One of the first studies showing that spironolactone on top of an ACE inhibitor lowers proteinuria.
11. Lit YZ, Meyer TW. More work to do on renin-angiotensin system blockade. Clin J Am Soc Nephrol 2006; 1:611-612.
12. Sato A, Hayashi K, Saruta T. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 2005; 18:44-49.
13. Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003; 41:64-68.
14. Bianchi S, Bigazzi R, Campese VM. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. Am J Kidney Dis 2005; 46:45-51.
15. Rump LC. Secondary rise of albuminuria under AT1-receptor blockade - what is the potential role of aldosterone escape? Nephrol Dial Transplant 2007; 22:5-8.
16. Ibsen H, Olsen MH, Wachtell K, et al. Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. Diabetes Care 2006; 29:595-600.
17. Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 2006; 70:2116-2123. First study showing that spironolactone on top of an ACE inhibitor or an AT1 antagonist may delay progression of CKD.
18. Weinberger MH, Luft FC. Comprehensive suppression of the reninangiotensin-aldosterone system in chronic kidney disease: covering all of the bases. Kidney Int 2006; 70:2051-2053.
19. Kramer A, van der Meulen E, Hamming I, et al. Effect of combining ACE-inhibition with aldosterone blockade on proteinuria and renal damage in experimental nephrosis. Kidney Int 2007; 71:417-424.
20. Juknevicius I, Segal Y, Kren S, et al. Effect of aldosterone on renal transforming growth factor-beta. Am J Physiol Renal Physiol 2004; 286:F1059-F1062.
21. Hamming I, Navis G, Kocks MJ, van Goor H. ACE inhibition has adverse renal effects during dietary sodium restriction in proteinuric and healthy rats. J Pathol 2006; 209:129-139.
22. Nguyen G, Delarue F, Burckle C, et al. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002; 109:1417-1427.
23. Saris JJ, van den Eijnden MM, Lamers JM, et al. Prorenin-induced myocyte proliferation: no role for intracellular angiotensin II. Hypertension 2002; 39:573-577.
24. Huang Y, Wongamorntham S, Kasting J, et al. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int 2006; 69:105-113. Convincing data showing that binding of renin to the (pro)renin receptor induces profibrotic signalling independent of angiotensin II.
25. Krebs C, Hamming I, Sadaghiani S, et al. Antihypertensive therapy upregulates renin and (pro)renin receptor in the clipped kidney of Goldblatt hypertensive rats. Kidney Int 2007; 72:725-730; Jun 27 [Epub ahead of print]. First study showing an upregulation of renin and the (pro)renin receptor in renovascular hypertension.
26. Hamming I, Goor H, Navis GJ. ACE inhibitor use and the increased long-term risk of renal failure in diabetes. Kidney Int 2006; 70:1377-1378.